Markr Gilbert News Today

Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab Survival

BERLIN--(BUSINESS WIRE)--Regulatory News:NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today it has entered into a material transfer agreement with the U.S. National Cancer Institute (NCI), of...